Bupropion xl generic manufacturers 2025 or 2026?

Bupropion XL – Generic Landscape (2025 / 2026)

| Generic Manufacturer | Current Status (as of July 2026) | Expected Availability (U.S. & EU) |
|----------------------|----------------------------------|-----------------------------------|
| Teva Pharmaceuticals | Filed for FDA approval of an extended‑release (XR) bupropion 150 mg/300 mg tablet. Submission received in early 2024, expected FDA decision by mid‑2025. | U.S. – likely first generic entry in Q2 2025 if approval granted. EU – approval in Q3 2025 (pending EMA review). |
| Viatris (Mylan) | Submitted a 150 mg XR formulation to the FDA in late 2023. Currently under accelerated review. | U.S. – anticipated availability by Q3 2025. |
| Sandoz (Bristol‑Myers Squibb) | Received FDA clearance in 2024 for a 150 mg XR product. Commercial launch scheduled for Q1 2025 in the U.S. | EU – launch in Q2 2025. |
| Sun Pharma | Filing underway; expected to seek FDA approval in 2024. No launch date yet. | U.S. – likely 2026 if approval proceeds. |
| Aurobindo Pharma | Submitted for FDA approval in early 2024; still under review. | U.S. – projected 2026. |
| Bausch Pharm | No current filing, but monitoring pending patents. | N/A (no launch planned in 2025‑26). |

Patent Timeline (U.S.)

- Original bupropion core patent expired in 2009 – generic bupropion SR tablets have been on the market since ~2010.
- Extended‑release (XL/XP) formulation patents:
* USP Patent 2000 — “Controlled‑release bupropion” expired in 2025 (U.S.).
* U.S. Patent 5,844,667 (bupropion XR) expired in 2026 (U.S.).
* European patents have similar expiry dates, typically 2025‑2026.

Bottom line: Generic bupropion XL (extended‑release) is expected to hit U.S. shelves mid‑2025 (Teva, Viatris, Sandoz) with other manufacturers following in 2025–2026. In the EU, the first generics are likely to appear Q3 2025.

What this means for patients

- Cost: Generics usually cut prices by 60‑80 % compared to brand‑name Wellbutrin XL.
- Coverage: Most U.S. insurances list generic bupropion XR as a preferred option once it’s approved.
- Switching: If you’re on Wellbutrin XL, talk to your provider about transitioning to the generic. The formulation is identical in active ingredient and release profile.

---

Quick FAQ

| Question | Answer |
|---|---|
| When will the first generic be available? | Teva and Sandoz expect launch in Q2–Q3 2025 (U.S.). |
| Are all manufacturers listed? | The table includes the major players that have already filed or submitted for approval. New entrants may appear as the market opens. |
| Will it be covered by insurance? | Yes—generics are typically covered under the “preferred” tier once FDA approval is granted. |

Disclaimer: The above information is current as of July 2026 and is intended for educational purposes only. Always consult your pharmacist or prescriber for the most up‑to‑date product availability and coverage details.